Condition
Berger Disease
Total Trials
5
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
P 2 (3)
P 3 (2)
Trial Status
Active Not Recruiting2
Terminated1
Enrolling By Invitation1
Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07498335Phase 3RecruitingPrimary
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT06674577Phase 2Enrolling By Invitation
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
NCT07020923Phase 2Active Not Recruiting
Monthly Dosing of Atacicept in IgAN
NCT04716231Phase 3Active Not Recruiting
Atacicept in Subjects With IgA Nephropathy
NCT03841448Phase 2Terminated
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Showing all 5 trials